Investment case
Royalty Pharma plc
RPRX · 3 developments mapped · last assessed 2026-09-05
Market Ontology has mapped 3 macro, policy, and market developments to Royalty Pharma plc since 2026-09-05. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for RPRX yet, so no modelled value is shown. The RPRX valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run RPRX on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Open question
Novartis Phase 3 Pelacarsen Cardiovascular Trial Misses Primary Endpoint
Loss of potential future royalty income from pelacarsen, offset by expected capital recovery.
· Moves future royalty streams, investment return expectations
What changed, by assumption
- 2026-09-05Novartis Phase 3 Pelacarsen Cardiovascular Trial Misses Primary Endpoint
- 2026-09-05Novartis Phase 3 Pelacarsen Trial Fails Primary Cardiovascular Endpoint
- 2026-09-05Novartis Pelacarsen Phase 3 Trial Fails; Royalty Pharma Expects to Recoup $500M
Assumption changes
Full ledger →| Date | Assumption | Direction | Why | Conf. |
|---|---|---|---|---|
| 2026-08-05 | Net debt | Bearish | Liability-management transactions often reduce gross debt or push maturities out. | 0.70 |
| 2026-08-05 | Interest expense | Bearish | Tender/exchange extends maturity profile and typically lowers near-term interest expense. | 0.70 |
| 2026-08-05 | Share count | Bullish | Stock component of consideration dilutes existing acquirer holders. | 0.70 |
| 2026-08-05 | Net debt | Bullish | Cash component of consideration is typically debt-funded, raising net debt. | 0.70 |
| 2026-08-05 | Revenue | Bullish | Acquisition adds target revenue to acquirer P&L on close. | 0.70 |
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-09-05 | Novartis Phase 3 Pelacarsen Trial Fails Primary Cardiovascular Endpoint | mixed | 1-3m | 0.40 |
| 2026-09-05 | Novartis Pelacarsen Phase 3 Trial Fails; Royalty Pharma Expects to Recoup $500M | mixed | 1-3m | 0.40 |
| 2026-09-05 | Novartis Phase 3 Pelacarsen Cardiovascular Trial Misses Primary Endpoint | mixed | 1-3m | 0.60 |